# ELI LILLY & Co

Summary updated: 2026-03-18T22:37:33.051164Z
Canonical: https://finbar.com/research/companies/eli-lilly-co

## Overview

Eli Lilly and Company is a U.S.-based pharmaceutical company founded in Indiana in 1901, succeeding a drug manufacturing business established in Indianapolis in 1876. It operates in a single business segment focused on human pharmaceutical products, and its core activities are discovering, developing, manufacturing, and marketing medicines. Lilly states that its purpose is to “unite caring with discovery to create medicines that make life better for people around the world.” [1](https://app.finbar.com/go?id=P-412f4f1b4bce4d429104dc8904e42a46)[2](https://app.finbar.com/go?id=P-4de53225b8614c999ce079fcf342e35e)

The company’s business is defined by major therapeutic areas including immunology, metabolism—covering diabetes, obesity, and cardiovascular disease—neuroscience, and oncology. Its marketed portfolio includes products in cardiometabolic health, cancer, immunology, and neuroscience, with well-known medicines such as Mounjaro and Zepbound in metabolic disease and Verzenio, Taltz, Emgality, and Kisunla in other specialty areas. [3](https://app.finbar.com/go?id=P-29994f5c07e5414d9f8f657998acf0c7)[4](https://app.finbar.com/go?id=P-de021be422a446ca9f40b0987b43c073)[5](https://app.finbar.com/go?id=P-e11da722382f4fff83eb80ae88c8a8bd)[6](https://app.finbar.com/go?id=P-086a552863584810b693c5bcb33fe590)

Lilly has a broad international footprint, manufacturing and distributing products through facilities in the United States, including Puerto Rico, as well as Europe and Asia, and selling its medicines in approximately 95 countries. As a general indicator of scale, the company employed about 47,000 people at the end of 2024, including roughly 25,000 outside the U.S., and generated $45.0 billion in 2024 revenue. [7](https://app.finbar.com/go?id=P-45942fa7cc3a4eb493899bbcda8f47fc)[8](https://app.finbar.com/go?id=P-1ae3f6d77e824a2c8052f25658264a04)[9](https://app.finbar.com/go?id=T-3804b4dba4d444109452b4973eacde86)
[1](https://app.finbar.com/go?id=P-412f4f1b4bce4d429104dc8904e42a46)[2](https://app.finbar.com/go?id=P-4de53225b8614c999ce079fcf342e35e)[3](https://app.finbar.com/go?id=P-29994f5c07e5414d9f8f657998acf0c7)[4](https://app.finbar.com/go?id=P-de021be422a446ca9f40b0987b43c073)[5](https://app.finbar.com/go?id=P-e11da722382f4fff83eb80ae88c8a8bd)[6](https://app.finbar.com/go?id=P-086a552863584810b693c5bcb33fe590)[7](https://app.finbar.com/go?id=P-45942fa7cc3a4eb493899bbcda8f47fc)[8](https://app.finbar.com/go?id=P-1ae3f6d77e824a2c8052f25658264a04)[9](https://app.finbar.com/go?id=T-3804b4dba4d444109452b4973eacde86)

## Products & services

Eli Lilly reports a single business segment of human pharmaceutical products, and its marketed portfolio is organized mainly across cardiometabolic health, oncology, immunology and neuroscience [2](https://app.finbar.com/go?id=P-4de53225b8614c999ce079fcf342e35e). In cardiometabolic health, key products include Mounjaro (tirzepatide) for adults with type 2 diabetes; Zepbound (tirzepatide) for obesity or overweight with a weight-related comorbidity and for obstructive sleep apnea in adults with obesity; Trulicity for type 2 diabetes and cardiovascular risk reduction in certain patients; Jardiance for type 2 diabetes and cardiorenal indications; Basaglar as a long-acting human insulin analog; Humalog as a family of insulin analog products including Mix 75/25, U-100, U-200, Mix 50/50 and insulin lispro; and Humulin as recombinant-DNA human insulin products including 70/30, N, R and U-500 [5](https://app.finbar.com/go?id=P-e11da722382f4fff83eb80ae88c8a8bd).

Its oncology portfolio includes Cyramza for several gastric, gastroesophageal junction, non-small cell lung, colorectal and liver cancer settings; Erbitux for colorectal and certain head and neck cancers; Jaypirca for mantle cell lymphoma and certain CLL/SLL patients; Retevmo for RET-driven lung, thyroid and other solid tumors; Tyvyt for multiple cancer indications in China; and Verzenio for HR-positive, HER2-negative metastatic and high-risk early breast cancer [6](https://app.finbar.com/go?id=P-086a552863584810b693c5bcb33fe590). In immunology and neuroscience, Lilly markets Ebglyss for moderate to severe atopic dermatitis, Olumiant for rheumatoid arthritis, atopic dermatitis and alopecia areata, Omvoh for ulcerative colitis and Crohn’s disease, Taltz for psoriasis and spondyloarthritis indications, Emgality for migraine prevention and episodic cluster headache, and Kisunla for early symptomatic Alzheimer’s disease [10](https://app.finbar.com/go?id=T-51c793234a26442b9e6219b6965e8b0e).

Product concentration is high in cardiometabolic medicines: in 2024 Mounjaro generated $11.54 billion, or about 25.6% of total company revenue; Verzenio $5.31 billion, or 11.8%; Trulicity $5.25 billion, or 11.7%; Zepbound $4.93 billion, or 10.9%; Jardiance $3.34 billion, or 7.4%; Taltz $3.26 billion, or 7.2%; and Humalog $2.32 billion, or 5.2% [11](https://app.finbar.com/go?id=P-0f650b3fca814438927140abd32909fb). At the therapeutic-area level, cardiometabolic health contributed $29.52 billion, or about 65.5% of 2024 revenue, compared with $8.75 billion from oncology, $4.39 billion from immunology and $1.47 billion from neuroscience [12](https://app.finbar.com/go?id=P-3d0b4419e9b647e0ba114635fd88c035).
[2](https://app.finbar.com/go?id=P-4de53225b8614c999ce079fcf342e35e)[5](https://app.finbar.com/go?id=P-e11da722382f4fff83eb80ae88c8a8bd)[6](https://app.finbar.com/go?id=P-086a552863584810b693c5bcb33fe590)[10](https://app.finbar.com/go?id=T-51c793234a26442b9e6219b6965e8b0e)[11](https://app.finbar.com/go?id=P-0f650b3fca814438927140abd32909fb)[12](https://app.finbar.com/go?id=P-3d0b4419e9b647e0ba114635fd88c035)

## Geographic presence

Eli Lilly’s operating footprint spans the United States, including Puerto Rico, as well as Europe and Asia, and its products are sold in approximately 95 countries. Its principal domestic and international executive offices are in Indianapolis. The company owns production, distribution, and corporate administrative sites in the U.S., with major production sites in Indiana, North Carolina, Puerto Rico, and New Jersey, and it also owns production and distribution sites in Europe and Asia, with major sites in Ireland, France, Spain, Italy, China, and Japan. Outside the U.S., Lilly maintains its own sales organizations in many countries and also uses third parties for some commercial sales operations.[7](https://app.finbar.com/go?id=P-45942fa7cc3a4eb493899bbcda8f47fc)[13](https://app.finbar.com/go?id=P-85f8119175a741a58831d4f61eb404ad)[14](https://app.finbar.com/go?id=P-4d6fd702a22c4b4ea5712bdeff743cb0)

In 2024, Lilly reported $45.0 billion of revenue by customer location, of which $30.4 billion, or 67.4%, came from the U.S. and $14.7 billion, or 32.6%, from outside the U.S. Its largest disclosed non-U.S. regions and countries were Europe at $6.9 billion, or 15.4% of total revenue, Japan at $1.8 billion, or 4.0%, China at $1.7 billion, or 3.7%, and rest of world at $4.3 billion, or 9.5%.[15](https://app.finbar.com/go?id=T-8960fd7658604bbf8c9edd1a4dfd51b6)[16](https://app.finbar.com/go?id=P-7cd718f4cbe84a62b9f80d42b3e2f4ba)

At the end of 2024, Lilly employed approximately 47,000 people, including approximately 25,000 employees outside the U.S. Its research footprint includes owned facilities in Indiana and leased sites in California, Massachusetts, New York, and Colorado in the U.S., plus a small owned R&D facility in Spain and a small leased site in Singapore.[8](https://app.finbar.com/go?id=P-1ae3f6d77e824a2c8052f25658264a04)[17](https://app.finbar.com/go?id=P-92ccc194120944fc9dd7c7c4d583d965)
[7](https://app.finbar.com/go?id=P-45942fa7cc3a4eb493899bbcda8f47fc)[13](https://app.finbar.com/go?id=P-85f8119175a741a58831d4f61eb404ad)[14](https://app.finbar.com/go?id=P-4d6fd702a22c4b4ea5712bdeff743cb0)[15](https://app.finbar.com/go?id=T-8960fd7658604bbf8c9edd1a4dfd51b6)[16](https://app.finbar.com/go?id=P-7cd718f4cbe84a62b9f80d42b3e2f4ba)[8](https://app.finbar.com/go?id=P-1ae3f6d77e824a2c8052f25658264a04)[17](https://app.finbar.com/go?id=P-92ccc194120944fc9dd7c7c4d583d965)

## Business segments

Eli Lilly does not report multiple operating segments. It describes itself as operating in a single business segment—human pharmaceutical products—and, more specifically, as a single reportable segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide; on that basis, essentially 100% of consolidated revenue and profit sit within one reportable segment [1](https://app.finbar.com/go?id=P-412f4f1b4bce4d429104dc8904e42a46)[18](https://app.finbar.com/go?id=P-2a69cf0e00194c69bd8575fed028cd3a).

Instead of reporting separate business segments, Lilly disaggregates revenue by therapeutic area. In 2024, Cardiometabolic Health was the largest category at about 65.5% of revenue, reflecting products such as Mounjaro, Trulicity, Zepbound, Jardiance, Humalog, and other diabetes/obesity-related medicines; Oncology contributed about 19.4%, led by products including Verzenio, Cyramza, Erbitux, and Tyvyt; Immunology contributed about 9.8%, mainly including Taltz and Olumiant; Neuroscience contributed about 3.3%, including Emgality and Zyprexa; and Other accounted for about 2.0% [19](https://app.finbar.com/go?id=P-0c22b6a8df664d7b9878128a4061588a)[20](https://app.finbar.com/go?id=T-3bc3e1b31e394614ab9b8b25d728af2e).

Lilly also provides a geographic revenue breakdown rather than geographic operating segments. In 2024, the U.S. accounted for about 67.4% of revenue, Europe about 15.4%, Japan about 4.0%, China about 3.7%, and the rest of the world about 9.5%, with revenue attributed based on customer location [21](https://app.finbar.com/go?id=P-b8d0deb9cf884438917419615eeaaa8b)[22](https://app.finbar.com/go?id=P-1c32eee1492544a1ba1f4dfb23397c6c)[15](https://app.finbar.com/go?id=T-8960fd7658604bbf8c9edd1a4dfd51b6).
[1](https://app.finbar.com/go?id=P-412f4f1b4bce4d429104dc8904e42a46)[18](https://app.finbar.com/go?id=P-2a69cf0e00194c69bd8575fed028cd3a)[19](https://app.finbar.com/go?id=P-0c22b6a8df664d7b9878128a4061588a)[20](https://app.finbar.com/go?id=T-3bc3e1b31e394614ab9b8b25d728af2e)[21](https://app.finbar.com/go?id=P-b8d0deb9cf884438917419615eeaaa8b)[22](https://app.finbar.com/go?id=P-1c32eee1492544a1ba1f4dfb23397c6c)[15](https://app.finbar.com/go?id=T-8960fd7658604bbf8c9edd1a4dfd51b6)

## Company history

Eli Lilly and Company traces its origins to 1876, when Colonel Eli Lilly founded a drug manufacturing business in Indianapolis; the present company was incorporated in Indiana in 1901 to succeed that business.[1](https://app.finbar.com/go?id=P-412f4f1b4bce4d429104dc8904e42a46) A major early milestone came in 1923, when Lilly introduced Iletin, which the company describes as the world’s first commercially available insulin product.[23](https://www.lilly.com/about/history)

Over the following decades, Lilly’s history was marked by several important product and corporate milestones. The company introduced Humulin in 1982 as human insulin made with recombinant DNA technology, launched Prozac in 1988, and added Humalog in 1996.[24](https://uspl.lilly.com/humulinru100/humulinru100.html)[25](https://www.lilly.com/company/about-lilly/milestones-of-caring-and-discovery)[26](https://uspl.lilly.com/humalog/humalog.html) In 2008, Lilly completed the acquisition of ImClone Systems, expanding its oncology business.[27](https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-imclone-systems) A later structural change came with the separation of its animal-health business, Elanco, through a 2018 IPO and the disposition of Lilly’s remaining ownership in 2019.[28](https://app.finbar.com/go?id=P-cfca7f8861de4de2908ca56ba33dc4e9)[29](https://app.finbar.com/go?id=P-f3262ace87f047e2a45c89432492a147) David Ricks became president and CEO in 2017, marking a leadership transition after John Lechleiter’s retirement.[30](https://investor.lilly.com/news-releases/news-release-details/john-c-lechleiter-retire-lilly-ceo-board-elects-david-ricks)
[1](https://app.finbar.com/go?id=P-412f4f1b4bce4d429104dc8904e42a46)[28](https://app.finbar.com/go?id=P-cfca7f8861de4de2908ca56ba33dc4e9)[29](https://app.finbar.com/go?id=P-f3262ace87f047e2a45c89432492a147)[23](https://www.lilly.com/about/history)[24](https://uspl.lilly.com/humulinru100/humulinru100.html)[25](https://www.lilly.com/company/about-lilly/milestones-of-caring-and-discovery)[26](https://uspl.lilly.com/humalog/humalog.html)[27](https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-imclone-systems)[30](https://investor.lilly.com/news-releases/news-release-details/john-c-lechleiter-retire-lilly-ceo-board-elects-david-ricks)

## Sources

1. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-412f4f1b4bce4d429104dc8904e42a46)
2. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-4de53225b8614c999ce079fcf342e35e)
3. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-29994f5c07e5414d9f8f657998acf0c7)
4. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-de021be422a446ca9f40b0987b43c073)
5. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-e11da722382f4fff83eb80ae88c8a8bd)
6. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-086a552863584810b693c5bcb33fe590)
7. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-45942fa7cc3a4eb493899bbcda8f47fc)
8. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-1ae3f6d77e824a2c8052f25658264a04)
9. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=T-3804b4dba4d444109452b4973eacde86)
10. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=T-51c793234a26442b9e6219b6965e8b0e)
11. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-0f650b3fca814438927140abd32909fb)
12. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-3d0b4419e9b647e0ba114635fd88c035)
13. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-85f8119175a741a58831d4f61eb404ad)
14. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-4d6fd702a22c4b4ea5712bdeff743cb0)
15. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=T-8960fd7658604bbf8c9edd1a4dfd51b6)
16. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-7cd718f4cbe84a62b9f80d42b3e2f4ba)
17. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-92ccc194120944fc9dd7c7c4d583d965)
18. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-2a69cf0e00194c69bd8575fed028cd3a)
19. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-0c22b6a8df664d7b9878128a4061588a)
20. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=T-3bc3e1b31e394614ab9b8b25d728af2e)
21. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-b8d0deb9cf884438917419615eeaaa8b)
22. [ELI LILLY & Co — Full financial report (2024 Y)](https://app.finbar.com/go?id=P-1c32eee1492544a1ba1f4dfb23397c6c)
23. [www.lilly.com](https://www.lilly.com/about/history)
24. [uspl.lilly.com](https://uspl.lilly.com/humulinru100/humulinru100.html)
25. [www.lilly.com](https://www.lilly.com/company/about-lilly/milestones-of-caring-and-discovery)
26. [uspl.lilly.com](https://uspl.lilly.com/humalog/humalog.html)
27. [investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-imclone-systems)
28. [ELI LILLY & Co — Full financial report (2019 Y)](https://app.finbar.com/go?id=P-cfca7f8861de4de2908ca56ba33dc4e9)
29. [ELI LILLY & Co — Press release (2019 Q 1)](https://app.finbar.com/go?id=P-f3262ace87f047e2a45c89432492a147)
30. [investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/john-c-lechleiter-retire-lilly-ceo-board-elects-david-ricks)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.